Resources

GeminiBio opens new cGMP bioprocess liquid manufacturing facility, expanding capabilities to better serve the biotechnology and cell & gene therapy markets

Asahi Kasei Bioprocess America and GeminiBio enter strategic partnership to advance application of Inline Buffer Formulation and streamline biopharmaceutical manufacturing processes. The strategic partnership will establish a joint solution for the efficient creation of buffers created from concentrates delivered directly to manufacturing facilities, increasing productivity and speed to market. • Costs for biopharmaceutical production can be significantly reduced, positively affecting the accessibility of medication for patients globally. • This partnership will be a catalyst for innovation at both companies, driving new industry standards.

Projected growth to more than double by 2025

Senior biopharma and cell therapy engineering/operations executive with 30+ years of experience to help drive growth

CEO of California Life Sciences with extensive and varied experience across the life science ecosystem.

GeminiBio announces the launch of a new human AB serum product for the cell therapy and regenerative medicine markets.

Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, today announced the launch of new products designed to improve cell therapy manufacturing processes.

Gemini Bioproducts, LLC (“GeminiBio”), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne.

Matt Stober, CEO of Abzena, joins the Board at GeminiBio.